UNSPSC 51434923: Chlorthalidone/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434923 Chlorthalidone/reserpine is a Commodity code representing individual pharmaceutical products procured by state and local health agencies, municipalities, and cooperative purchasing alliances for emergency medical services, pharmacy benefit programs, and institutional health facilities. State and local governments buy this code to stock specific branded or generic medications for use in emergency response, medicaid and employee health benefit programs, and facility-based clinical care. Issuing bodies include municipal fire rescue services, state health and human services departments, and multistate cooperative purchasing organizations that aggregate demand across multiple jurisdictions. Recent solicitations show demand for both emergency medications (labetalol, epinephrine, adenosine, diltiazem) and generic multi-source pharmaceutical supply agreements that include chlorthalidone and related antihypertensive agents as part of broader pharmaceutical catalogs distributed through authorized wholesalers.

Activity under the code is concentrated in the South and Upper Midwest. The City of Tampa issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, designated as a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (Solicitation S1070000015802) due March 26, 2026 for Generic Multi Source Pharmaceuticals and OTC Products to supply participating state and local government facilities across Minnesota and Oregon through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with contracts effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) in early April 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory state-level interest in alternative pharmacy procurement models that may inform future formal solicitations.